Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Zomedica Corp. (ZOMDF) Q2 2026 Earnings Call Transcript

Collaboration with one of the world's largest animal health companies expected to accelerate TRUFORMA adoption, expand installed base, and drive recurring diagnostic revenue in Canada ANN ARBOR, MI / ACCESS Newswire / August 13, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic solutions for equine and companion animals, today announced a collaboration with Boehringer Ingelheim Animal Health Canada Inc., a leader in the animal health industry, to enhance the early detection, treatment, and monitoring of pituitary pars intermedia dysfunction (PPID) in horses across Canada. Through this initiative, the TRUFORMA system will support Boehringer Ingelheim's PPID awareness and testing efforts in Canada beginning with this fall testing season, enabling veterinarians to perform rapid endocrine testing at the point of care using Zomedica's equine endogenous ACTH (eACTH) and equine insulin assays.

August session to spotlight Zomedica's international expansion strategy, distributor infrastructure, global market opportunity, and the commercial leadership driving growth across five continents ANN ARBOR, MI / ACCESS Newswire / August 11, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the next installment of its "Fourth Friday at Four" investor webinar series, scheduled for Friday, August 28, 2026, at 4:00 p.m. Eastern Time.

Zomedica surpasses $9 million in second quarter revenue for the first time while extending its record of consecutive year-over-year revenue growth to 22 quarters. ANN ARBOR, MI / ACCESS Newswire / August 5, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the three and six months ended June 30, 2026.

The accessory reduces sound in the treatment environment while maintaining the trusted efficacy of PulseVet® shock wave therapy ANN ARBOR, MI / ACCESS Newswire / August 4, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of the PulseVet Acoustic Muffler, an innovative accessory designed to significantly reduce the acoustic noise associated with shock wave therapy treatments while preserving the clinical performance practitioners rely on. Developed for use with PulseVet shock wave therapy systems, the PulseVet Muffler™ accessory addresses the treatment noise associated with the sound waves produced by the PulseVet system.